533 related articles for article (PubMed ID: 19254354)
1. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.
Tack J; Masclee A; Heading R; Berstad A; Piessevaux H; Popiela T; Vandenberghe A; Kato H
Neurogastroenterol Motil; 2009 Mar; 21(3):272-80. PubMed ID: 19254354
[TBL] [Abstract][Full Text] [Related]
2. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.
Suzuki H; Hibi T
Neurogastroenterol Motil; 2010 Jun; 22(6):595-9. PubMed ID: 20553562
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
Matsueda K; Hongo M; Tack J; Aoki H; Saito Y; Kato H
Neurogastroenterol Motil; 2010 Jun; 22(6):618-e173. PubMed ID: 20059698
[TBL] [Abstract][Full Text] [Related]
4. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia.
Nakamura K; Tomita T; Oshima T; Asano H; Yamasaki T; Okugawa T; Kondo T; Kono T; Tozawa K; Ohda Y; Fukui H; Kazuhito F; Hirota S; Watari J; Miwa H
J Gastroenterol; 2017 May; 52(5):602-610. PubMed ID: 27639387
[TBL] [Abstract][Full Text] [Related]
5. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.
Tack J; Janssen P
Expert Opin Investig Drugs; 2011 May; 20(5):701-12. PubMed ID: 21417958
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia.
Tack J; Janssen P; Masaoka T; Farré R; Van Oudenhove L
Clin Gastroenterol Hepatol; 2012 Nov; 10(11):1239-45. PubMed ID: 22813445
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography.
Kusunoki H; Haruma K; Manabe N; Imamura H; Kamada T; Shiotani A; Hata J; Sugioka H; Saito Y; Kato H; Tack J
Neurogastroenterol Motil; 2012 Jun; 24(6):540-5, e250-1. PubMed ID: 22385472
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia.
Tack J; Van Den Elzen B; Tytgat G; Wajs E; Van Nueten L; De Ridder F; Boeckxstaens G
Neurogastroenterol Motil; 2009 Jun; 21(6):619-26, e23-4. PubMed ID: 19220756
[TBL] [Abstract][Full Text] [Related]
9. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia.
Miner PB; Rodriguez-Stanley S; Proskin HM; Kianifard F; Bottoli I
Curr Med Res Opin; 2008 Aug; 24(8):2159-72. PubMed ID: 18561877
[TBL] [Abstract][Full Text] [Related]
10. Effect of acotiamide on gastric emptying in healthy adult humans.
Zai H; Matsueda K; Kusano M; Urita Y; Saito Y; Kato H
Eur J Clin Invest; 2014 Dec; 44(12):1215-21. PubMed ID: 25370953
[TBL] [Abstract][Full Text] [Related]
11. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials.
Talley NJ; Tack J; Ptak T; Gupta R; Giguère M
Gut; 2008 Jun; 57(6):740-6. PubMed ID: 17965059
[TBL] [Abstract][Full Text] [Related]
12. Relationship between symptom pattern, assessed by the PAGI-SYM questionnaire, and gastric sensorimotor dysfunction in functional dyspepsia.
Kindt S; Dubois D; Van Oudenhove L; Caenepeel P; Arts J; Bisschops R; Tack J
Neurogastroenterol Motil; 2009 Nov; 21(11):1183-e105. PubMed ID: 19663903
[TBL] [Abstract][Full Text] [Related]
13. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration.
Matsueda K; Hongo M; Ushijima S; Akiho H
Digestion; 2011; 84(4):261-8. PubMed ID: 21934307
[TBL] [Abstract][Full Text] [Related]
14. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
Altan E; Masaoka T; Farré R; Tack J
Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):533-44. PubMed ID: 23061703
[TBL] [Abstract][Full Text] [Related]
15. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats.
Seto K; Sasaki T; Katsunuma K; Kobayashi N; Tanaka K; Tack J
Neurogastroenterol Motil; 2008 Sep; 20(9):1051-9. PubMed ID: 18482254
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers.
Choung RS; Talley NJ; Peterson J; Camilleri M; Burton D; Harmsen WS; Zinsmeister AR
Neurogastroenterol Motil; 2007 Mar; 19(3):180-7. PubMed ID: 17300287
[TBL] [Abstract][Full Text] [Related]
17. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying.
Arts J; Caenepeel P; Verbeke K; Tack J
Gut; 2005 Apr; 54(4):455-60. PubMed ID: 15753526
[TBL] [Abstract][Full Text] [Related]
18. Predictors of the placebo response in functional dyspepsia.
Talley NJ; Locke GR; Lahr BD; Zinsmeister AR; Cohard-Radice M; D'Elia TV; Tack J; Earnest DL
Aliment Pharmacol Ther; 2006 Apr; 23(7):923-36. PubMed ID: 16573795
[TBL] [Abstract][Full Text] [Related]
19. Acotiamide improves stress-induced impaired gastric accommodation.
Ikeo K; Oshima T; Sei H; Kondo T; Fukui H; Watari J; Miwa H
Neurogastroenterol Motil; 2017 Apr; 29(4):. PubMed ID: 27860042
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
